Literature DB >> 15688404

Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands.

Johannes Berkhof1, Martine C de Bruijne, Gilda D Zielinski, Chris J L M Meijer.   

Abstract

A simulation model is presented that assumes that persistent infection with high-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer. For the estimation of the model parameters, data of recent Dutch follow-up studies were reanalyzed. The predicted incidences of cervical cancer, cervical intraepithelial neoplasia (CIN1, CIN2 and CIN3) and abnormal cytology were validated with nationwide figures and population-based screening results. The model predicted a lifetime risk for cervical cancer of 2.9% with a peak at age 48 years. The predicted lifetime risk dropped to 0.4% when attending cervical screening. For women who were not hrHPV infected at 30 years, the lifetime risk was 1.6%. Sensitivity analyses were performed to check natural history assumptions that were only weakly identified from available data sets. The incidence of CIN3 observed with screening appeared a useful clinical end point as the predicted incidence was robust against changes in the sensitivity of cervical cytology and the duration to CIN3. The model can be used to study the health-economic benefits that can be achieved in nationwide screening when including an hrHPV test. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Year:  2005        PMID: 15688404     DOI: 10.1002/ijc.20846

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.

Authors:  Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 2.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.

Authors:  Inge M C M de Kok; Joost van Rosmalen; Joakim Dillner; Marc Arbyn; Peter Sasieni; Thomas Iftner; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2012-03-05

4.  Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.

Authors:  S Bulk; J Berkhof; N W J Bulkmans; G D Zielinski; L Rozendaal; F J van Kemenade; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

5.  Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.

Authors:  Xiao Li; Martinus P Stander; Georges Van Kriekinge; Nadia Demarteau
Journal:  BMC Infect Dis       Date:  2015-12-11       Impact factor: 3.090

Review 6.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

7.  Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.

Authors:  Steffie K Naber; Suzette M Matthijsse; Kirsten Rozemeijer; Corine Penning; Inge M C M de Kok; Marjolein van Ballegooijen
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

8.  The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Authors:  Suzette M Matthijsse; Steffie K Naber; Jan A C Hontelez; Roel Bakker; Marjolein van Ballegooijen; Iris Lansdorp-Vogelaar; Inge M C M de Kok; Harry J de Koning; Joost van Rosmalen; Sake J de Vlas
Journal:  PLoS One       Date:  2018-09-04       Impact factor: 3.240

9.  Transcriptome changes induced by RUNX3 in cervical cancer cells in vitro.

Authors:  Qian-Qian Gao; Bin Zhou; Xiu-Zhang Yu; Zhu Zhang; Yan-Yun Wang; Ya-Ping Song; Lin Zhang; Hong Luo; Ming-Rong Xi
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.